Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ramipril Clear all
Completed Phase 2Phase 3 Interventional Results available

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

NCT00141778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Ramipril, Spironolactone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

The RAS, Fibrinolysis and Cardiopulmonary Bypass

NCT00607672
View directory record Official record
Conditions
Coronary Artery Disease, Angiotensin Converting Enzyme, Angiotensin Receptor Blockers, Cardiopulmonary Bypass, Fibrinolysis, Inflammation
Interventions
Placebo, Ramipril, Candesartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 4 Interventional

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

NCT00095290
View directory record Official record
Conditions
Albuminuria
Interventions
Ramipril + Irbesartan, Ramipril + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension

NCT00355589
View directory record Official record
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 25, 2026, 10:30 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

NCT00608465
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Eplerenone, Ramipril
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 25, 2026, 10:30 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes

NCT00574834
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Ramipril, HCTZ-hydrochlorothiazide, Ramipril+HCTZ
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

NCT01078363
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
ramipril, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

NCT00219063
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions

NCT00702260
View directory record Official record
Conditions
Hypertension
Interventions
Ramipril
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 25, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 25, 2026, 10:30 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Ramipril for the Treatment of COVID-19

NCT04366050
View directory record Official record
Conditions
COVID-19
Interventions
Ramipril 2.5 MG Oral Capsule, Placebo oral capsule
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 4 Interventional Results available

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

NCT01669434
View directory record Official record
Conditions
Hypotension on Induction
Interventions
ACEI continuation, ACEI omission
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

NCT03475186
View directory record Official record
Conditions
Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation
Interventions
Ramipril
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
422
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 280 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 4 Interventional

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

NCT00274599
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
19 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 25, 2026, 10:30 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 25, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional Results available

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

NCT00729365
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Gainesville, Florida • Chicago, Illinois • Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 25, 2026, 10:30 AM EDT
Completed No phase listed Observational

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

NCT04354350
View directory record Official record
Conditions
Hypertension
Interventions
Ramipril, Telmisartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years and older
Enrollment
63,744 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 25, 2026, 10:30 AM EDT
Not listed Phase 2 Interventional

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

NCT02791958
View directory record Official record
Conditions
Hypertension
Interventions
Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg
Drug
Lead sponsor
Ferrer Internacional S.A.
Industry
Eligibility
18 Years to 74 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 25, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928
View directory record Official record
Conditions
Atherosclerosis, Coronary Disease, Vasculitis
Interventions
Ramipril
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 10:30 AM EDT